HAE NYSE
Haemonetics Corporation
1W: +1.5%
1M: +13.4%
3M: +40.5%
YTD: +50.0%
1Y: +134.1%
3Y: +34.7%
5Y: +72.8%
$119.97
+0.78 (+0.65%)
After Hours: $117.00 (-2.97, -2.48%)
Weekly Expected Move ±9.2%
$97
$108
$118
$129
$140
Credit Risk of going bust: lower than 51% of companies Debt: 17.8% of company value Bonds: $84.5M held by 32 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $2.47 (down 98%), Haemonetics Corporation would be worth roughly what it owes.
Total debt $1.17B against a stock market value of $5.42B.
Distance to default 5.19 (Merton model): prices to 2026-10-26, balance sheet 2026-06-27, debt counted $589.6M (short-term plus half of long-term), stock volatility 48.2%; Altman Z 3.37. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $2.47 (down 98%), Haemonetics Corporation would be worth roughly what it owes.
Total debt $1.17B against a stock market value of $5.42B.
Distance to default 5.19 (Merton model): prices to 2026-10-26, balance sheet 2026-06-27, debt counted $589.6M (short-term plus half of long-term), stock volatility 48.2%; Altman Z 3.37. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
All You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy
Haemonetics wins approval of PerQseal Elite vascular closure system
Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
Haemonetics (NYSE:HAE) Hits New 52-Week High – Still a Buy?
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
These healthcare stocks have the highest EPS revision grade ahead of Q3 results
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Haemonetics advances 17% on CSL supply deal
Biggest stock movers Thursday: Crypto stocks, MRVL, APLD, and more
Haemonetics gains after update on CSL supply deal
PAHC vs. HAE: Which Stock Is the Better Value Option?
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
444,351 Shares in Haemonetics Corporation $HAE Acquired by Bank of America Corp DE
Engineers Gate Manager LP Has $897,000 Holdings in Haemonetics Corporation $HAE
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
Haemonetics upgraded to Buy at BofA on supply deal with CSL
GEHC vs. HAE: Which Stock Is the Better Value Option?
Algert Global LLC Has $3.52 Million Stock Position in Haemonetics Corporation $HAE
Aurora Investment Counsel Acquires New Position in Haemonetics Corporation $HAE
Here's Why Haemonetics (HAE) is a Strong Momentum Stock
At a glance: stocks gapping up premarket
Haemonetics rises after supply deal with CSL
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up
Haemonetics (HAE) Q1 2027 Earnings Call Transcript
Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know
Haemonetics Corporation Q1 2027 Earnings Call Summary
Haemonetics (HAE) Tops Q1 Earnings and Revenue Estimates
Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Perrigo (PRGO) Surpasses Q2 Earnings and Revenue Estimates
Earnings Preview: Haemonetics (HAE) Q1 Earnings Expected to Decline
Martin Madaus Elected to Haemonetics Board of Directors
American Capital Management Inc. Sells 7,500 Shares of Haemonetics Corporation $HAE
Aurora Investment Counsel Takes Position in Haemonetics Corporation $HAE
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Haemonetics Updates Financial Reporting Segments
Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends
Is the Options Market Predicting a Spike in Haemonetics Stock?
HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut
Haemonetics (HAE) Q4 2026 Earnings Transcript
Haemonetics projects FY 2027 revenue growth of 4% to 7% as Persona PLUS rollout and IVT rebound efforts continue
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics Non-GAAP EPS of $1.29 beats by $0.02, revenue of $346M beats by $9.14M
Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Envista (NVST) Surpasses Q1 Earnings and Revenue Estimates
Haemonetics Q4 2026 Earnings Preview
Boston Trust Walden Corp Sells 376,040 Shares of Haemonetics Corporation $HAE
Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation
Mizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide Review
Haemonetics Corporation (NYSE:HAE) Given Average Rating of “Moderate Buy” by Brokerages
Harbor Capital Advisors Inc. Sells 22,228 Shares of Haemonetics Corporation $HAE
Allspring Global Investments Holdings LLC Sells 121,063 Shares of Haemonetics Corporation $HAE
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
Assenagon Asset Management S.A. Sells 99,083 Shares of Haemonetics Corporation $HAE
Zacks Research Forecasts Stronger Earnings for Haemonetics
Q3 EPS Estimates for Haemonetics Lifted by Zacks Research
Haemonetics Corporation $HAE Shares Sold by Confluence Investment Management LLC
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
Here's Why Haemonetics (HAE) is a Strong Value Stock
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report?
Why Is Zimmer (ZBH) Down 2% Since Last Earnings Report?
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Haemonetics Corporation $HAE Shares Acquired by Barrow Hanley Mewhinney & Strauss LLC
Elo Mutual Pension Insurance Co Takes $829,000 Position in Haemonetics Corporation $HAE
Here's Why Haemonetics (HAE) is a Strong Value Stock
Ameritas Investment Partners Inc. Has $636,000 Holdings in Haemonetics Corporation $HAE
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
Haemonetics (HAE) International Revenue Performance Explored
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Haemonetics Q3 Earnings Call Highlights
These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings
Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips
Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026
Haemonetics (HAE) Reports Q3 Earnings: What Key Metrics Have to Say
Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates
Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Haemonetics (HAE) is a Strong Growth Stock
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
Will Haemonetics (HAE) Beat Estimates Again in Its Next Earnings Report?
Haemonetics Expands Heart Surgery Arsenal With Vivasure Acquisition
Vivasure Medical Announces Acquisition by Haemonetics Corporation
Haemonetics Acquires Vivasure Medical Limited
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term